Dick de Zeeuw
#96,840
Most Influential Person Now
Researcher
Dick de Zeeuw's AcademicInfluence.com Rankings
Dick de Zeeuwcomputer-science Degrees
Computer Science
#3364
World Rank
#3530
Historical Rank
Computational Linguistics
#158
World Rank
#162
Historical Rank
Machine Learning
#383
World Rank
#388
Historical Rank
Artificial Intelligence
#574
World Rank
#585
Historical Rank
Download Badge
Computer Science
Dick de Zeeuw's Degrees
- PhD Computer Science University of Amsterdam
- Masters Artificial Intelligence University of Oxford
- Bachelors Computer Science University of Amsterdam
Similar Degrees You Can Earn
Why Is Dick de Zeeuw Influential?
(Suggest an Edit or Addition)Dick de Zeeuw's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. (2001) (5071)
- Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). (2005) (3290)
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (2017) (3090)
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. (2019) (2717)
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial (2011) (2093)
- Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population (2002) (1585)
- Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis (2003) (1137)
- Cardiorenal end points in a trial of aliskiren for type 2 diabetes. (2012) (1133)
- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2002) (1120)
- A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. (2009) (1106)
- Renal function, neurohormonal activation, and survival in patients with chronic heart failure. (2000) (1032)
- Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. (2004) (967)
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. (2004) (956)
- Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure (2006) (859)
- Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. (2013) (796)
- Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy (2004) (746)
- Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity (2001) (681)
- Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease (2001) (679)
- Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial (2010) (678)
- Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. (2011) (645)
- Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease (2012) (637)
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes (2013) (630)
- Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria (2004) (564)
- Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. (2001) (529)
- The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. (2003) (517)
- ABSENCE OF CROSS-REACTIVITY BETWEEN CAPTOPRIL AND ENALAPRIL (1984) (505)
- Erythropoietic response and outcomes in kidney disease and type 2 diabetes. (2010) (421)
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. (2018) (410)
- Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. (1989) (402)
- Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. (2001) (389)
- GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. (2014) (388)
- Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials (2009) (380)
- Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. (2000) (374)
- Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. (2008) (352)
- Microalbuminuria as an early marker for cardiovascular disease. (2006) (345)
- A central body fat distribution is related to renal function impairment, even in lean subjects. (2003) (342)
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus (2018) (334)
- Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? (1994) (317)
- Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. (2009) (311)
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events (2017) (308)
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. (2013) (307)
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (2019) (306)
- Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. (2007) (305)
- Smoking Is Related to Albuminuria and Abnormal Renal Function in Nondiabetic Persons (2000) (301)
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. (2011) (287)
- Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. (1995) (277)
- Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. (2008) (248)
- An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. (2004) (244)
- C-reactive protein is associated with renal function abnormalities in a non-diabetic population. (2003) (225)
- First morning voids are more reliable than spot urine samples to assess microalbuminuria. (2009) (223)
- Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. (2019) (218)
- The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. (2014) (217)
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016) (214)
- Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. (2012) (213)
- The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. (1998) (212)
- Reduction of proteinuria by angiotensin converting enzyme inhibition. (1987) (207)
- A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. (1997) (207)
- The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. (2015) (205)
- Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. (2006) (205)
- Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. (2015) (203)
- Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes (2014) (201)
- The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review (2004) (200)
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups (2019) (191)
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function (2018) (186)
- Dual renin-angiotensin system blockade at optimal doses for proteinuria. (2002) (182)
- Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis (2021) (181)
- The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics (2017) (180)
- Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. (2006) (179)
- Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. (2008) (179)
- Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. (1999) (176)
- Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. (2003) (176)
- Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial (2011) (174)
- The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. (2005) (174)
- Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy (1996) (172)
- The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. (2002) (169)
- Excessive Urinary Albumin Levels Are Associated With Future Cardiovascular Mortality in Postmenopausal Women (2001) (167)
- Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. (1989) (165)
- Comparison of different measures of urinary protein excretion for prediction of renal events. (2010) (163)
- Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. (1994) (161)
- Diabetic Kidney Disease– A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) (2014) (154)
- Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. (2012) (151)
- Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. (1995) (146)
- The kidney, a cardiovascular risk marker, and a new target for therapy. (2005) (145)
- Screening for albuminuria identifies individuals at increased renal risk. (2009) (145)
- Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. (2005) (143)
- Effects of lowering LDL cholesterol on progression of kidney disease. (2014) (140)
- The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. (2003) (140)
- Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. (2014) (136)
- Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. (2007) (135)
- Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration. (2005) (135)
- The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) (2000) (135)
- A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus (2013) (131)
- Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. (2003) (129)
- Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. (2012) (129)
- The glycocalyx—linking albuminuria with renal and cardiovascular disease (2015) (128)
- Gender differences in predictors of the decline of renal function in the general population. (2008) (127)
- Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. (2014) (127)
- Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran. (1996) (126)
- Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. (2011) (124)
- Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial (2017) (122)
- N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. (2010) (122)
- Urinary albumin excretion as a predictor of the development of hypertension in the general population. (2006) (119)
- Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase? (2003) (119)
- Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. (2005) (118)
- Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. (2011) (117)
- Microalbuminuria and Endothelial Dysfunction: Emerging Targets for Primary Prevention of End-organ Damage (2006) (116)
- Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. (2006) (116)
- Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. (1994) (114)
- Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. (2019) (113)
- Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. (2015) (112)
- Renoprotective therapy: titration against urinary protein excretion (1999) (110)
- C-Reactive Protein Modifies the Relationship Between Blood Pressure and Microalbuminuria (2004) (109)
- Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. (2004) (106)
- Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy (2014) (106)
- The association between atherosclerotic risk factors and renal function in the general population. (2005) (104)
- Atrial natriuretic factor: its (patho)physiological significance in humans. (1992) (104)
- Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials (2017) (99)
- Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. (1993) (96)
- Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and re (2004) (92)
- Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. (2004) (91)
- CAPTOPRIL AND THE IMMUNE SYSTEM (1981) (90)
- Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. (2004) (88)
- The effect of RAAS blockade on the progression of diabetic nephropathy (2014) (86)
- Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial. (2019) (86)
- Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. (2012) (86)
- Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. (1993) (85)
- Impact of weight change on albuminuria in the general population. (2007) (85)
- The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients (2017) (84)
- Extended prognostic value of urinary albumin excretion for cardiovascular events. (2008) (84)
- Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program (2019) (83)
- Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. (2020) (83)
- Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. (2002) (83)
- Effects of nonsteroidal anti-inflammatory drugs on proteinuria. (1986) (81)
- Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. (2019) (81)
- Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. (1987) (80)
- Antihypertensive Effect of a 5‐Day Infusion of Atrial Natriuretic Factor in Humans (1989) (80)
- Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. (2004) (80)
- Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. (1996) (80)
- Comparison of zofenopril and lisinopril to study the role of the sulfhydryl‐group in improvement of endothelial dysfunction with ACE‐inhibitors in experimental heart failure (2000) (80)
- Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) (2013) (79)
- ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. (2008) (79)
- High protein intake associates with cardiovascular events but not with loss of renal function. (2009) (79)
- Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes (2016) (77)
- Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus (2003) (77)
- Update on microalbuminuria as a biomarker in renal and cardiovascular disease (2006) (76)
- Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review (2012) (75)
- Falsely low urinary albumin concentrations after prolonged frozen storage of urine samples. (2005) (75)
- Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? (2004) (74)
- Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. (2020) (74)
- Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension? (1996) (73)
- Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). (2011) (72)
- Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. (1993) (72)
- Potential role of active vitamin D in retarding the progression of chronic kidney disease. (2006) (71)
- Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study (2016) (70)
- Renal handling of technetium-99m DMSA: evidence for glomerular filtration and peritubular uptake. (1989) (69)
- Relative risks of Chronic Kidney Disease for mortality and End Stage Renal Disease across races is similar (2014) (69)
- Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. (1997) (68)
- The kidney in type 2 diabetes therapy. (2011) (68)
- Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. (2004) (68)
- Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) (2012) (68)
- Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. (2014) (67)
- Microalbuminuria: target for renoprotective therapy PRO. (2014) (67)
- Early renin‐angiotensin system intervention is more beneficial than late intervention in delaying end‐stage renal disease in patients with type 2 diabetes (2016) (67)
- A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. (2005) (66)
- A Longitudinal Study Examining Adherence to Guidelines in Diabetes Care According to Different Definitions of Adequacy and Timeliness (2011) (66)
- C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. (2004) (65)
- Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria (2011) (65)
- Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. (1994) (64)
- Low Levels of Urinary Albumin Excretion Are Associated with Cardiovascular Risk Factors in the General Population (2000) (63)
- The reliability of different formulae to predict creatinine clearance (2003) (63)
- Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2009) (63)
- Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. (1991) (62)
- Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP) (2016) (60)
- Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy (2018) (60)
- Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial (2010) (60)
- Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. (2000) (60)
- Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis (2021) (60)
- Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. (2020) (60)
- Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. (2020) (60)
- Evaluation of measures of urinary albumin excretion. (2006) (60)
- Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition. (1991) (60)
- Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. (2018) (59)
- Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss. (2000) (59)
- Bilirubin and Progression of Nephropathy in Type 2 Diabetes: A Post Hoc Analysis of RENAAL With Independent Replication in IDNT (2014) (59)
- Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. (2020) (59)
- Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). (2014) (59)
- Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. (2006) (58)
- Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade (2003) (57)
- Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. (1992) (57)
- A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes (2015) (57)
- Diuretic Effects of Angiotensin‐Converting Enzyme Inhibition: Comparison of Low and Liberal Sodium Diet in Hypertensive Patients (1987) (57)
- Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD. (2018) (57)
- Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling. (1997) (57)
- Need for better diabetes treatment for improved renal outcome. (2011) (57)
- Risk factors for long-term renal survival after renal transplantation: a role for angiotensin-converting enzyme (insertion/deletion) polymorphism? (1998) (56)
- Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo. (1997) (56)
- Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. (1990) (55)
- Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial (2016) (55)
- Review: Relation Between Quality-of-Care Indicators for Diabetes and Patient Outcomes: A Systematic Literature Review (2011) (55)
- Reduction of urinary protein and prostaglandin E2 excretion in the nephrotic syndrome by non-steroidal anti-inflammatory drugs. (1986) (53)
- Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? (1997) (53)
- Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future? (2004) (53)
- Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. (2018) (52)
- ACE Inhibitors and the Kidney (1996) (52)
- Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program (2019) (51)
- The effect of RAAS blockade on the progression of diabetic nephropathy (2014) (50)
- Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome? (1993) (50)
- LISINOPRIL AND RENAL FAILURE (1989) (50)
- Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. (2001) (49)
- Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. (2020) (49)
- Monitoring Kidney Function and Albuminuria in Patients With Diabetes (2011) (49)
- Intracellular Angiotensin II and cell growth of vascular smooth muscle cells (2001) (49)
- Impaired coronary endothelial function in a rat model of spontaneous albuminuria. (2002) (48)
- Specific Drug Delivery to the Kidney (2002) (48)
- Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes (2012) (48)
- The role of angiotensin(1–7) in renal vasculature of the rat (2006) (47)
- Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. (2001) (47)
- Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality (2019) (46)
- Albuminuria: a target for treatment of type 2 diabetic nephropathy. (2007) (46)
- Apparent loss of urinary albumin during long-term frozen storage: HPLC vs immunonephelometry. (2007) (44)
- The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. (2015) (44)
- The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial (2005) (44)
- Canagliflozin and Stroke in Type 2 Diabetes Mellitus (2018) (43)
- Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats. (1999) (43)
- Delta9-tetrahydrocannabinol activates [Ca2+]i increases partly sensitive to capacitative store refilling. (1997) (43)
- Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? (2004) (42)
- Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable? (2000) (42)
- Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study (2005) (42)
- Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy (2015) (41)
- The Geographical Distribution of Leadership in Globalized Clinical Trials (2012) (41)
- Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. (1996) (41)
- Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. (2000) (41)
- What predicts progression and regression of urinary albumin excretion in the nondiabetic population? (2007) (41)
- Unmet need in diabetic nephropathy: failed drugs or trials? (2016) (41)
- Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy (2010) (41)
- LDL cholesterol in CKD--to treat or not to treat? (2013) (41)
- Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. (1997) (41)
- Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia (2014) (40)
- Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes (2017) (40)
- Metabolic syndrome: a fata morgana? (2006) (40)
- Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme. (1999) (40)
- Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease (2021) (39)
- Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy (2013) (39)
- ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients. (1997) (39)
- Novel drugs and intervention strategies for the treatment of chronic kidney disease (2013) (39)
- Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. (2015) (39)
- Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. (2005) (39)
- Effect of human atrial natriuretic peptide on blood pressure after sodium depletion in essential hypertension. (1986) (39)
- Kinetically stable complexes of alkali cations with calixspherands : An evaluation of shielding (1994) (39)
- Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats. (2008) (39)
- Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population (2012) (39)
- The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial (2014) (38)
- The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics (2009) (38)
- Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial (2010) (38)
- Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. (1985) (38)
- Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial (2015) (38)
- Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. (2008) (38)
- Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial (2011) (37)
- Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy (2012) (37)
- Albuminuria: a target for treatment of type 2 diabetic nephropathy. (2007) (37)
- Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study (2013) (37)
- Altered myogenic constriction and endothelium-derived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotally nephrectomized rats (2006) (36)
- Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat. (2010) (36)
- Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. (1999) (35)
- Prolonged frozen storage of urine reduces the value of albuminuria for mortality prediction. (2007) (35)
- ACE-inhibitors: panacea for progressive renal disease? (1997) (35)
- Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. (2008) (35)
- NEPHROPTOSIS AND HYPERTENSION (1977) (35)
- Antiproteinuric effect of naproxen and indomethacin. A double-blind crossover study. (1985) (35)
- Proteinuria and progression of renal disease: therapeutic implications (1997) (35)
- Quantification of renal low-molecular-weight protein handling in the intact rat. (1993) (35)
- Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? (2002) (35)
- Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998–2004: a longitudinal observational study (2007) (34)
- Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy? (2005) (34)
- Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. (1992) (34)
- Restenosis prevalence and long-term effects on renal function after percutaneous transluminal renal angioplasty. (1986) (34)
- International consensus definitions of clinical trial outcomes for kidney failure: 2020. (2020) (34)
- Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. (2016) (34)
- Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials? (2011) (33)
- Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta (1999) (33)
- Debate: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial (2010) (33)
- ACE Inhibition Preserves Heparan Sulfate Proteoglycans in the Glomerular Basement Membrane of Rats with Established Adriamycin Nephropathy (2000) (33)
- Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers (2016) (33)
- Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. (2000) (33)
- Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. (2015) (32)
- Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease (2021) (32)
- Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II (2004) (32)
- Biochemical risk markers: a novel area for better prediction of renal risk? (2005) (31)
- Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium Intake. (2015) (31)
- A population-based screening for microalbuminuria among relatives of CKD patients: the Kidney Evaluation and Awareness Program in Sheffield (KEAPS). (2008) (31)
- Diagnostic use of angiotensin converting enzyme inhibitors in radioisotope evaluation of unilateral renal artery stenosis. (1989) (31)
- Endothelial dysfunction and infarct‐size relate to impaired EDHF response in rat experimental chronic heart failure (2003) (31)
- Differential Effects of Comorbidity on Antihypertensive and Glucose-Regulating Treatment in Diabetes Mellitus – A Cohort Study (2012) (31)
- Microalbuminuria and C-reactive protein: Similar messengers of cardiovascular risk? (2005) (30)
- High Dietary Sodium Blunts Effects of Angiotensin-converting Enzyme Inhibition on Vascular Angiotensin I–to–Angiotensin II Conversion in Rats (2003) (30)
- POTENTIALS AND LIMITATIONS OF THE LOW-MOLECULAR-WEIGHT PROTEIN LYSOZYME AS A CARRIER FOR RENAL DRUG TARGETING (2001) (30)
- Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. (2002) (30)
- Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats (2003) (30)
- Angiotensin-converting enzyme gene I/D polymorphism and renal disease (1999) (30)
- Role of the endothelin-1 gene locus for renal impairment in the general nondiabetic population. (2003) (30)
- Renoprotection with and without blood pressure reduction. (2005) (29)
- Gene therapy with adenovirus‐delivered indoleamine 2,3‐dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat (2011) (29)
- Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery. (1999) (29)
- The Importance of Short‐Term Off‐Target Effects in Estimating the Long‐Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers (2014) (29)
- An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials (2012) (29)
- Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation (2017) (29)
- Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes (2020) (28)
- Approaches and methods in gene therapy for kidney disease. (2004) (28)
- Coronary Myogenic Constriction Antagonizes EDHF-Mediated Dilation: Role of KCa Channels (2003) (28)
- Change in albuminuria is predictive of cardiovascular outcome in normotensive patients with type 2 diabetes mellitus and microalbuminuria (2007) (28)
- Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. (2003) (28)
- Enhanced transduction of fibroblasts in transplanted kidney with an adenovirus having an RGD motif in the HI loop. (2006) (28)
- The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program (2019) (27)
- Does the European clinical trials directive really improve clinical trial approval time? (2008) (27)
- Renal and cardio-protective effects of direct renin inhibition: a systematic literature review (2009) (27)
- Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. (2020) (27)
- Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. (1999) (27)
- Renoprotective effects of renin-angiotensin-system inhibitors (2006) (27)
- Effect of frozen storage on urinary concentration of kidney damage markers. (2012) (27)
- Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events. (2012) (27)
- Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. (2018) (26)
- A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers (2014) (26)
- Composite renal endpoints: was ACCOMPLISH accomplished? (2010) (26)
- Effect of first myocardial ischemic event on renal function. (2007) (25)
- A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients (2011) (25)
- Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire (2013) (25)
- Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. (2015) (25)
- Hypertension and renal disease: role of microalbuminuria. (1996) (25)
- Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis (2021) (25)
- Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. (2002) (25)
- Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction? (2006) (25)
- Low Molecular Weight Proteins as Carriers for Renal Drug Targeting: Naproxen–Lysozyme (1991) (25)
- SERUM URIC ACID, ACE INHIBITORS, AND NATRIURESIS (1985) (25)
- Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. (2021) (24)
- Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome (1995) (24)
- The angiotensin converting enzyme inhibitor enalapril and its effects on renal function. (1983) (24)
- Albuminuria in heart failure: what do we really know? (2009) (24)
- The blood pressure lowering potential of sulodexide--a systematic review and meta-analysis. (2015) (24)
- Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) (2016) (24)
- Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies (2007) (24)
- Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension: The Prevention of Renal and Vascular End-Stage Disease Study. (2015) (24)
- How to measure the prevalence of microalbuminuria in relation to age and gender? (2002) (24)
- [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. (2001) (23)
- Efficacy and safety of Canagliflozin (CANA), an inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), added on to insulin therapy with or without oral agents in type 2 diabetes (T2D) (2013) (23)
- Low-molecular-weight proteins as carriers for renal drug targeting. (1993) (23)
- Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action. (1991) (23)
- Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. (2013) (23)
- Variability in response to albuminuria‐lowering drugs: true or random? (2017) (23)
- Endothelial function predicts the development of renal damage after combined nephrectomy and myocardial infarction. (2006) (23)
- Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes (2015) (23)
- Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease. (2001) (22)
- Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database (2013) (22)
- Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease? (2008) (22)
- Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results: A post hoc analysis of the RENAAL trial results (2004) (22)
- A novel approach for establishing cardiovascular drug efficacy (2014) (22)
- Drug targeting to the kidney with low-molecular-weight proteins (1994) (22)
- Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone-system intervention. (2006) (22)
- Drug delivery to the kidneys and the bladder with the low molecular weight protein lysozyme. (1998) (22)
- High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case–control study with confirmation in diabetes (2013) (22)
- Volume homeostasis, angiotensin converting enzyme inhibition, and lithium therapy. (1989) (22)
- Intracellular angiotensin II elicits Ca2+ increases in A7r5 vascular smooth muscle cells. (2001) (22)
- Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo (2004) (22)
- The influence of indomethacin on renal concentrating and diluting capacity in sickle cell nephropathy. (1982) (22)
- Claims in advertisements for antihypertensive drugs in a Dutch medical journal (2007) (22)
- NT‐proBNP by Itself Predicts Death and Cardiovascular Events in High‐Risk Patients With Type 2 Diabetes Mellitus (2020) (22)
- The Antiproteinuric Effect of Angiotensin-Converting-Enzyme Inhibitors in Human Renal Disease (1991) (21)
- Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function (1999) (21)
- Targeting proteinuria as a valid surrogate for individualized kidney protective therapy (2008) (21)
- Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study. (2016) (21)
- Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors. (2010) (21)
- Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. (2014) (21)
- Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats. (1999) (20)
- Predictors of Progression in Albuminuria in the General Population: Results from the PREVEND Cohort (2013) (20)
- New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. (2020) (20)
- Impact of CKD on Household Income (2017) (20)
- Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis. (2000) (20)
- Low Sodium Modifies the Vascular Effects of Angiotensin-Converting Enzyme Inhibitor Therapy in Healthy Rats (2004) (20)
- Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy (2012) (20)
- Low Molecular Weight Proteins as Carriers for Renal Drug Targeting: Naproxen Coupled to Lysozyme via the Spacer L-Lactic Acid (1993) (20)
- Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. (2013) (20)
- The antiproteinuric effect of antihypertensive agents in diabetic nephropathy. (1992) (20)
- Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial. (2020) (20)
- Atrial natriuretic peptide-induced decreases in renal blood flow in man: implications for the natriuretic mechanism. (1989) (20)
- Renal specific delivery of sulfamethoxazole in the rat by coupling to the low molecular weight protein lysozyme via an acid-sensitive linker (1992) (19)
- Renoprotection: a matter of blood pressure reduction or agent-characteristics? (2002) (19)
- Noninvasive measurement of intrarenal blood flow distribution: kinetic model of renal 123I-hippuran handling. (1995) (19)
- Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus (2009) (19)
- Unmet Need in Renal Protection – Do We Need a More Comprehensive Approach? (2011) (19)
- Effects of enalaprilic acid on sodium excretion and renal hemodynamics in essential hypertension. (1985) (19)
- The End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade? (2013) (19)
- A comparison of analytic procedures for measurement of fractional dextran clearances. (1998) (18)
- Association Between Performance Measures and Glycemic Control Among Patients With Diabetes in a Community-wide Primary Care Cohort (2013) (18)
- Urinary prostaglandins in sickle cell nephropathy: a defect in 9-ketoreductase activity? (1984) (18)
- Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to aNalyse Type 2 diabetes Treatment (GIANTT) observational study (2010) (18)
- Targeting of Doxorubicin to the Urinary Bladder of the Rat Shows Increased Cytotoxicity in the Bladder Urine Combined With An Absence of Renal Toxicity (2002) (18)
- Omics-bioinformatics in the context of clinical data. (2011) (18)
- Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. (1996) (18)
- Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial. (2018) (18)
- Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome. (2016) (18)
- Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. (2005) (18)
- Renal function as a predictor of prognosis in chronic heart failure. (2002) (17)
- Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. (2021) (17)
- Enalapril and the Kidney: Renal Vasodilation and Natriuresis Due to the Inhibition of Angiotensin II Formation (1986) (17)
- Physicians’ attitudes towards treatment guidelines: differences between teaching and nonteaching hospitals (2006) (17)
- Effect of chronic ACE inhibition on the diagnostic value of renography for renovascular hypertension: a preliminary report. (1995) (17)
- ACE inhibitors and proteinuria (1996) (17)
- Adenovirus‐mediated interleukin‐13 gene therapy attenuates acute kidney allograft injury (2007) (17)
- Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events. (2013) (17)
- Does comorbidity explain trends in prescribing of newer antihypertensive agents? (2004) (17)
- A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics (2018) (17)
- Urine collection in the freely moving rat: reliability for measurement of short-term renal effects. (1997) (17)
- Review: Intracellular angiotensin II: from myth to reality? (2001) (17)
- Should albuminuria be a therapeutic target in patients with hypertension and diabetes (2004) (17)
- FUNCTIONALIZED CALIXSPHERANDS - SYNTHESIS AND PEPTIDE COUPLING (1994) (16)
- Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damage. (2008) (16)
- Do Treatment Quality Indicators Predict Cardiovascular Outcomes in Patients with Diabetes? (2013) (16)
- Does Angiotensin (1-7) Contribute to the Antiproteinuric Effect of ACE-inhibitors? (2005) (16)
- A method for accurate measurement of GFR in conscious, spontaneously voiding rats. (1997) (16)
- Sodium depletion enhances the antiproteinuric effect of ACE inhibition in established experimental nephrosis. (1992) (16)
- Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention. (2008) (16)
- Baseline characteristics and enrichment results from the SONAR trial (2018) (16)
- Urinary pH affects albumin concentrations after prolonged frozen storage. (2007) (16)
- The antihypertensive and renal effects of angiotensin II receptor antagonists: remaining questions. (2000) (16)
- Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries (2018) (15)
- Prevalence and distribution of (micro)albuminuria in toddlers. (2016) (15)
- Normalization of aortic function during arousal episodes in the hibernating ground squirrel. (2002) (15)
- Discordant effects of enalapril and lisinopril on systemic and renal hemodynamics (1994) (15)
- The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy (2017) (15)
- Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program (2020) (15)
- Comparing Adverse Event Rates of Oral Blood Glucose-Lowering Drugs Reported by Patients and Healthcare Providers (2011) (15)
- Dual RAS Therapy Not on Target, but Fully Alive (2010) (15)
- Changes in renal function induced by ACE-inhibition in the conscious two-kidney, one-clip Goldblatt hypertensive dog. (1992) (15)
- Novel anti-inflammatory drugs for the treatment of diabetic kidney disease (2016) (15)
- Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol (2020) (14)
- Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study (2016) (14)
- Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition? (2018) (14)
- Renin inhibition improves pressure natriuresis in essential hypertension. (2000) (14)
- Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable. (1999) (14)
- Albuminuria, just a marker for cardiovascular disease, or is it more? (2005) (14)
- Albuminuria, just a marker for cardiovascular disease, or is it more? (2005) (14)
- Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction (2004) (14)
- Proteinuria: a risk factor for pregnancy-related renal function decline in primary glomerular disease? (1995) (14)
- Immune modulation and graft protection by gene therapy in kidney transplantation. (2008) (14)
- The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. (2009) (13)
- Renal targeting of a non-steroidal anti-inflammatory drug: effects on renal prostaglandin synthesis in the rat. (1998) (13)
- Dual renin-angiotensin system blockade and kidney disease. (2009) (13)
- Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aorta (2002) (13)
- Relevance of correction for drift and day-to-day variation in cystatin C measurement: a post-hoc analysis of the PREVEND cohort, with independent replication in the ESTHER cohort (2015) (13)
- Renal hemodynamic effects of candesartan in normal and impaired renal function in humans. (1997) (13)
- Chapter 2 Angiotensin-converting enzyme gene I / D polymorphism and renal disease (2002) (13)
- Discontinuation of RAAS Inhibition in Children with Advanced CKD. (2020) (13)
- Angiotensin-converting enzyme inhibition-induced changes in hippurate renography and renal function in renovascular hypertension. (1996) (13)
- Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy (2006) (13)
- Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer. (2000) (13)
- Highly sensitive measurement of indomethacin using a high-performance liquid chromatographic technique combined with post-column in-line hydrolysis. (1986) (13)
- Titrating for antiproteinuric effect: the clue to renoprotection? (1996) (13)
- Lisinopril in hypertensive patients with renal function impairment. (1990) (13)
- Sample dilution: a methodological pitfall in the measurement of tissue but not serum ace-activity. (1998) (13)
- Measurement of glomerular charge selectivity in non-diabetic renal disease. (1997) (13)
- Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial (2018) (12)
- Improving clinical trial efficiency by biomarker-guided patient selection (2014) (12)
- Regulation of [Ca2+]i homeostasis in MRP1 overexpressing cells (2000) (12)
- Renal trials in diabetes need a platform: time for a global approach? (2017) (12)
- Effects of enalapril on blood pressure and renal haemodynamics in essential hypertension. (1983) (12)
- Erythrocyte Na+/Li+ countertransport and Na+/K+-2Cl- co-transport measurement in essential hypertension: useful diagnostic tools or failure? A meta-analysis of 17 years of literature. (1998) (12)
- Unmet need in renal protection--do we need a more comprehensive approach? (2011) (12)
- Screening and monitoring for albuminuria: the performance of the HemoCue point-of-care system. (2008) (12)
- Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis (2004) (11)
- Relation Between Quality-of-Care Indicators for Diabetes and Patient Outcomes: A Systematic Literature Review (2011) (11)
- Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study (2016) (11)
- Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study (2014) (11)
- Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. (2020) (11)
- Angiotensin Converting Enzyme Inhibition Improves Diagnostic Procedures for Renovascular Hypertension in Dogs (1988) (11)
- Restenosis of the renal artery after percutaneous transluminal renal angioplasty: an inevitable outcome? (1983) (11)
- The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders (2014) (11)
- Nephroptosis and kidney function. (1978) (11)
- CKD treatment: time to alter the focus to albuminuria? (2011) (11)
- Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program (2019) (11)
- The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidemia in response to antiproteinuric treatment. (1996) (11)
- 35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts. (1999) (11)
- Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night? (1997) (11)
- Renal end points in clinical trials of kidney disease (2015) (11)
- The Role of Patients’ Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes (2015) (11)
- Albuminuria: What can we expect from the determination of nonimmunoreactive albumin? (2009) (10)
- Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure. (2002) (10)
- Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight (2018) (10)
- I/D polymorphism of the angiotensin converting enzyme gene: a clue to the heterogeneity in the progression of renal disease and in the renal response to therapy? (1997) (10)
- ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. (2017) (10)
- Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy (2020) (10)
- The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics. (1992) (10)
- Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats (2002) (10)
- Nephrotic syndrome preceding Hodgkin's disease by 42 months. (1986) (10)
- Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial. (2021) (10)
- Mechanism of the antiproteinuric effect of angiotensin-converting enzyme inhibition. (1990) (10)
- N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk (2018) (10)
- Unilateral renal parenchymal disease with contralateral renal artery stenosis of the fibrodysplasia type. (1989) (10)
- Angiotensin-I converting enzyme inhibition: clinical effects in chronic renal disease. (1991) (10)
- Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies (2016) (10)
- Should albuminuria be a therapeutic target in patients with hypertension and diabetes? (2004) (9)
- Is the antiproteinuric effect of dipyridamole hemodynamically mediated? (1988) (9)
- Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. (2016) (9)
- Intracellular angiotensin II inhibits heterologous receptor stimulated Ca2+ entry. (2001) (9)
- Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease (2021) (9)
- Uptake of angiotensin II receptor blockers in the treatment of hypertension (2005) (9)
- ONTARGET still OFF-TARGET? (2011) (9)
- Drug-induced changes in renal hippurate clearance as a measure of renal blood flow. (1995) (9)
- Is the antiproteinuric effect of dipyridamole hemodynamically mediated (1988) (9)
- Effect of antiproteinuric treatment on the lipid profile in nondiabetic renal disease. (1997) (9)
- A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension (2006) (8)
- Treatment of idiopathic membranous nephropathy: the dilemma of who, when, and how. (1995) (8)
- Effects of fosinopril and pravastatin on cardiovascular events in microalbuminuric subjects. Results of PREVEND IT (2004) (8)
- Clinical trial in nephrology at hard end point (2004) (8)
- Comparison of urine collection methods for albuminuria assessment in young children. (2016) (8)
- Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats. (2008) (8)
- Does a low-salt diet exert a protective effect on endothelial function in normal rats? (2001) (8)
- Pharmacology: Defining the optimal dose of a new drug: a crucial decision (2009) (8)
- Indomethacin secretion in the isolated perfused proximal straight rabbit tubule. Evidence for two parallel transport mechanisms. (1988) (8)
- Beneficial effects of add‐on hydrochlorothiazide in rats with myocardial infarction optimally treated with quinapril (2005) (8)
- Letter regarding article by Klausen et al, "very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes". (2005) (8)
- Direct interaction between the sympathetic and renin-angiotensin system in myocardial tissue: a microdialysis study in anaesthetised rats. (2000) (8)
- Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease: the potential of exploring the mechanisms of response variability (2002) (8)
- Enhancement of screening tests for renovascular hypertension by angiotensin-converting enzyme inhibition. (1993) (8)
- Atrial natriuretic factor influences renal diurnal rhythm in essential hypertension. (1992) (8)
- Clearance of indometacin occurs predominantly by renal glucuronidation (1992) (8)
- Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study (2018) (8)
- A Comparison of Progression in Diabetic and Non-Diabetic Renal Disease: Similarity of Progression Promoters (2000) (7)
- ACE inhibitors and tissue binding (1990) (7)
- Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score? (2009) (7)
- Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. (2017) (7)
- The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale and design (2018) (7)
- Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709 (2011) (7)
- Renal effects of ketanserin in essential hypertension. (1986) (7)
- Renal and Systemic Effects of the Renin Inhibitor Remikiren in Patients with Essential Hypertension (1995) (7)
- Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis (2022) (7)
- CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS (2020) (7)
- Renal disease: a common and a silent killer (2008) (7)
- Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries. (2000) (7)
- Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial (2020) (6)
- Renoprotective therapy: is it blood pressure or albuminuria that matters? (2005) (6)
- Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial (2017) (6)
- Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes. (2011) (6)
- The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function (2021) (6)
- Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing HypertensionNovelty and Significance (2015) (6)
- The validity of a patient-reported adverse drug event questionnaire using different recall periods (2014) (6)
- [Quality of the treatment of type 2 diabetes: results from the GIANTT project 2004-2007]. (2010) (6)
- High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter] (2011) (6)
- Abstract #259 Cardiovascular and Renal Outcomes with Canagliflozin in People with Type 2 Diabetes According to Baseline use of Metformin (2019) (6)
- Role of proteinuria in the regulation of renal renin-angiotensin system components in unilateral proteinuric rats (2003) (6)
- The Abnormal Renal Vasodilator Response to D1-Like Receptor Stimulation in Conscious SHR Can Be Normalized by AT1 Blockade (2004) (6)
- Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition? (2002) (6)
- Efficacy and Safety of Canaglif lozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes (2014) (6)
- The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial (2020) (6)
- Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease (2019) (6)
- The mechanism and diagnostic value of angiotensin I converting enzyme inhibition renography. (1991) (5)
- Statins: cholesterol, blood pressure and beyond. (2002) (5)
- The future of Diabetic Kidney Disease management: reducing the unmet need (2020) (5)
- Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease. (2014) (5)
- Dual RAS Therapy Not on Target, but Fully Alive (2010) (5)
- The COOPERATE trial (2003) (5)
- ANTIPROTEINURIC EFFECT OF ACE INHIBITORS (1988) (5)
- Renal disease: a common and a silent killer. (2008) (5)
- Grams ME, Sang Y, Ballew SH, et al, for the Chronic Kidney Disease Prognosis Consortium. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93:1442-1451. (2018) (5)
- Is the randomized controlled drug trial in Europe lagging behind the USA? (2008) (5)
- A general method for the determination of the kinetic stability of macrocyclic alkali-metal complexes with rates of decomplexation below 10–3 s–1 (1994) (4)
- Drug Targeting to the Kidney: The Low-Molecular-Weight Protein Approach (2001) (4)
- Albuminuria: A New Target for Therapy? Treat the Kidney to Protect the Heart (2005) (4)
- Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects? (2017) (4)
- Losartan in patients with renal insufficiency. (1995) (4)
- 1159-194 Cystatin C, a novel risk marker for mortality in the general population: Data obtained from the PREVEND study (2004) (4)
- Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program (2021) (4)
- Treating diabetic complications; from large randomized clinical trials to precision medicine (2018) (4)
- Abstracts of papers (2005) (4)
- Delivery of Drugs and Antisense Oligonucleotides to the Proximal Tubular Cell of the Kidney Using Macromolecular and Pro‐drug Approaches (2001) (4)
- Effect of mild charge modification of albumin on renal excretion in the rat. (1988) (4)
- Reducing cardiovascular risk: protecting the kidney (2009) (4)
- Large Between-Patient Variability in eGFR Decline Before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy - A Post-Hoc Analysis From the SONAR Trial. (2021) (4)
- Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats (2003) (4)
- Comparison of exposure response relationship of atrasentan between North American and Asian populations (2017) (4)
- Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials (2018) (4)
- Quantification of renal low-molecular-weight protein degradation in the intact rat. (1993) (4)
- The end of dual therapy with renin-angiotensin-aldosterone system blockade? (2013) (4)
- Detecting and managing patients with type 2 diabetic kidney disease: proteinuria and cardiovascular disease. (2004) (4)
- Clinical trial in nephrology at hard end point? (2004) (4)
- Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease (2020) (4)
- Relief of renal artery stenosis: a tool to improve or preserve renal function in renovascular disease? (1990) (4)
- Future and Novel Compounds in the Treatment of Diabetic Nephropathy (2018) (4)
- [Methods of collecting urine for the determination of microalbuminuria: time for consensus]. (2004) (4)
- EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL (2020) (4)
- Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial (2021) (3)
- Renal endothelial function is associated with the anti-proteinuric effect of ACE inhibition in 5/6 nephrectomized rats. (2016) (3)
- Are post-trial observational studies useful? (2014) (3)
- The Pathophysiology of Proteinuria (2015) (3)
- Optimizing the renal response to ace inhibition: a strategy toward more effective long-term renoprotection. (1997) (3)
- Renal mobility and hypertension (1980) (3)
- Cardiovascular endocrinology: Dual RAAS blockade has dual effects on outcome (2013) (3)
- Renal tubular sensitivity to atrial natriuretic factor in essential hypertension (1994) (3)
- Unilateral renal parenchymal disease with contralateral renal artery stenosis of the fibrodysplasia type. (1989) (3)
- How to measure and monitor albuminuria in healthy toddlers? (2018) (3)
- Renoprotective therapy: is it blood pressure or albuminuria that matters? (2005) (3)
- Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis (2021) (3)
- Angiotensin converting enzyme inhibition induces alterations to hippuran renography despite unchanged ipsilateral renal blood flow in conscious two‐kidney, one clip Goldblatt hypertensive dogs (1988) (3)
- RELIEF OF RENAL-ARTERY STENOSIS - A TOOL TO IMPROVE OR PRESERVE RENAL-FUNCTION IN RENOVASCULAR DISEASE (1990) (3)
- Abstracts of papers and posters (2005) (3)
- Endothelin Receptor Antagonists for Kidney Protection. (2022) (3)
- Micro-HPLC and transfer techniques for directly measuring drug (indomethacin) transport across the isolated perfused renal proximal straight tubule. (1988) (3)
- EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL (2020) (2)
- MP427BASELINE DATA FROM THE MULTINATIONAL PROSPECTIVE COHORT STUDY FOR VALIDATION OF BIOMARKERS (PROVALID) (2016) (2)
- A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores (2021) (2)
- Can angiotensin II be used for renoprotection? (2002) (2)
- Pathophysiology of Proteinuria: Albuminuria as a Target for Treatment (2020) (2)
- Unilateral kidney blood flow measurement using the 81Rb/81mKr ratio. (1978) (2)
- Blood pressure response to enalaprilic acid in essential hypertension: Dose-response and effect of pre-treatment with furosemide (2004) (2)
- Determination of dopaminergic prodrugs by high-performance liquid chromatography followed by post-column ion-pair extraction. (1997) (2)
- The paradox created by commenting on large clinical trial results (2015) (2)
- Dual RAAS blockade has dual effects on outcome. (2013) (2)
- Renal hemodynamics in human hypertension (2000) (2)
- Renal 131I-hippurate clearance overestimates true renal blood flow in the instrumented conscious dog. (1996) (2)
- Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat. (2003) (2)
- SP457CCR2 INHIBITOR CCX140 EFFECTIVE IN PHASE 2 CLINICAL TRIAL IN DIABETIC NEPHROPATHY (2015) (2)
- The effect of transluminal dilation of stenosed renal arteries on kidney function. (1983) (2)
- Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study. (2023) (2)
- Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes (2003) (2)
- Do diabetic kidneys deserve a lifestyle change (2014) (2)
- Paricalcitol for reduction of albuminuria in diabetes – Authors' reply (2011) (2)
- Salt-The Forgotten Renal Risk Factor: Sodium Intake Affects Urinary Albumin Excretion Especially in Overweight Subjects. J Intern Med 256: 324-330, 2004. (2005) (2)
- Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial (2011) (2)
- Independent and combined effects of low sodium diet and diuretic on the antiproteinuric efficacy of the AT1 antagonist losartan in non-diabetic proteinuric patients (2008) (2)
- skeletal muscle during exercise: is there a controversy? Intramuscular triacylglycerol utilization in human (2015) (2)
- Semi-micro method for the determination of cation flux rate constants in erythrocytes. (1985) (2)
- Atrial natriuretic peptides: a new dimension in the understanding of volume homoeostasis? (1986) (1)
- Heart failure induced by aleglitazar treatment can be predicted based on short-term response in multiple risk markers (2016) (1)
- Endothelin Receptor Antagonists for Kidney Protection Lessons from the SONAR Trial (2022) (1)
- Immune-unreactive urinary albumin as a predictor of cardiovascular events: the Hortega Study. (2019) (1)
- Can continuous intraperitoneal infusion of 125I-iothalamate and 131I-hippuran be used for measurement of GFR in conscious rats? (1998) (1)
- How to Attain Optimal Antiproteinuric Dose of Losartan in Non-Diabetic Patients with Nephrotic Range Proteinuria (2002) (1)
- ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap (2016) (1)
- Accelerated progression of renal function loss after two pregnancies in a patient with proteinuria (1992) (1)
- Albuminuria: A sign of vascular problems? (2006) (1)
- Pharmacological zero for electromagnetic renal blood flow measurement (1985) (1)
- Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program (2021) (1)
- Patient Outcomes : A Systematic Literature Review Review : Relation Between Quality-of-Care Indicators for Diabetes and (2011) (1)
- Letters (2000) (1)
- Short-term effects of percutaneous transluminal renal angioplasty on renal function in unilateral renal artery stenosis. (1986) (1)
- SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS (2020) (1)
- Renal determinants for sodium sensitivity of blood pressure - Response (1996) (1)
- Human plasma contains low molecular weight factors which stimulate active sodium transport in erythrocytes. (1989) (1)
- Comparison of the Capabilities of a Midregional Fragment of the Pro–A-Type Natriuretic Peptide and the N-Terminal Pro–B-Type Natriuretic Peptide for Predicting Mortality and Cardiovascular Events (2011) (1)
- ONTARGET still OFF-TARGET? (2011) (1)
- Taurine as Reference Standard in Chromatography of Plant Material Extracts. (1964) (1)
- iation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes (2012) (1)
- Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625–637 (2018) (1)
- The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. (2020) (1)
- The link between mechanical stretch and glucose metabolism—a conceptual advance in understanding diabetic (and non diabetic?) renal disease (2007) (1)
- Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin (2019) (1)
- NT-PROBNP AND HSTNT IMPROVE CARDIOVASCULAR RISK PREDICTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY OR CARDIOVASCULAR DISEASE OR BOTH (2014) (1)
- The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial. (2022) (1)
- Prognosis of renal manifestations of Henoch-Schönlein syndrome in adults. A retrospective study of 18 patients. (1986) (1)
- Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting (2021) (1)
- EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE OUTCOMES WITH AND WITHOUT PRESERVED EJECTION FRACTION IN TYPE 2 DIABETES: RESULTS FROM THE CANVAS PROGRAM (2019) (1)
- 129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial (2021) (1)
- Consistent Outcomes with Canagliflozin (CANA) in Patients with Type 2 Diabetes across Geographic Regions—Results from the CANagliflozin CardioVascular Assessment Study (CANVAS) Program (2018) (1)
- Haemodynamics of renal artery stenosis (a comment based on Ohm's law) (1985) (1)
- OPTIMAL DOSING TIME FOR THE LONG-ACTING ACE INHIBITOR TRANDOLAPRIL IN NON-DIABETIC KIDNEY DISEASE: PP.24.468 (2010) (1)
- Involvement of atrial natriuretic peptide in long-term regulation of sodium-homeostasis in man. (1988) (1)
- Tuesday, 28 August 2012 (2012) (1)
- The selective type A endothelin antagonist atrasentan reduces residual albuminuria in patients with type 2 diabetes and nephropathy (2013) (1)
- Differences in erythrocyte sodium transport between human plasma and artificial medium: the role and character of sodium efflux and influx stimulating plasma factors. (1992) (1)
- PS11 - 1. Longitudinal eGFR trajectories in patients with type 2 diabetes (2013) (0)
- Treating Microalbuminuria-Cosmetic Exercises with Urine Chemistry or Effective Reduction of Clinical Events?: Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects with Microalbuminuria. Circulation 110: 2809-2816, 2004. (2005) (0)
- Author response for "SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes" (2020) (0)
- University of Groningen Association Between Performance Measures and Glycemic Control Among Patients With Diabetes in a Community-wide Primary Care Cohort Sidorenkov, (2013) (0)
- Practice of Epidemiology Albuminuria Assessed From First-Morning-Void Urine Samples Versus 24-Hour Urine Collections as a Predictor of Cardiovascular Morbidity and Mortality (2008) (0)
- Author Index, Supple 1, Vol. 55, 1990 (1990) (0)
- Contents Vol. 40, No. 4, 2015 (2015) (0)
- Use and validation of BIOMARKERS and proxy-outcomes in pre- and post-registration setting (2008) (0)
- C-reactiveand microalbuminuriain their associations with various domains of vascular (2004) (0)
- Symposium: renal aspects of cardiovascular pharmacotherapy: Specific drug delivery to the kidney (2003) (0)
- 1203-P: Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program (2019) (0)
- Abstract 3487: NT-proBNP Independently Predicts Cardiovascular Morbidity And Mortality In The General Population (2007) (0)
- OPTIMIZING RENOPROTECTION: INTERVENTION IN NEW PATHOPHYSIOLOGICAL PATHWAYS (2008) (0)
- Connecting BIOMARKERS and proxy-outcomes across different phases of drug development (2008) (0)
- D2-Like Receptor Stimulation Decreases Effective Renal Plasma Flow and Glomerular Filtration Rate in Spontaneously Hypertensive Rats (2002) (0)
- assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients (2011) (0)
- Albuminuria: A Target for Treatment in Diabetic and Non-Diabetic Nephropathy (2015) (0)
- DiagnosticUse of AngiotensinConverting EnzymeInhibitors in RadioisotopeEvaluation of Unilateral Renal ArteryStenosis (1989) (0)
- University of Groningen Differential effects of comorbidity on antihypertensive and glucose-regulating treatment in diabetes mellitus Voorham, (2012) (0)
- 1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program (2019) (0)
- with attenuated hypertrophic response in rats with myocardial infarction Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated (2013) (0)
- Contents, Vol. 22, 1978 (1973) (0)
- Diabetes: ROADMAP: the road to renoprotection? (2011) (0)
- Best practice for hypertensive patients with kidney disease. (2003) (0)
- Reply: Mediators of the Effects of Canagliflozin on Heart Failure: Central Role of the Cardiorenal Axis. (2020) (0)
- [Angiotensin-converting enzyme inhibitors in the treatment of proteinuria]. (1991) (0)
- PRM96 Reliability of a Patient-Reported Adverse Drug Event Questionnaire (2012) (0)
- 1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial (2020) (0)
- Antiproteinuric e Y cacy of verapamil in comparison to trandolapril in non-diabetic renal disease (1998) (0)
- A new constrictor device for external induction of a long-term stable and irreversible renal artery stenosis in the dog (1988) (0)
- Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial (2022) (0)
- University of Groningen N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk Idzerda, (2018) (0)
- Spotlight: Dick de Zeeuw, MD, PhD (2011) (0)
- Title Page. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial? (2010) (0)
- Atrasentan in patients with diabetes and chronic kidney disease – Authors' reply (2020) (0)
- Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. (2023) (0)
- PS12 Cont’d - 62. Prescribing of aliskiren in practice: findings from the GIANTT diabetes (2012) (0)
- Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program (2018) (0)
- Low molecular weight proteins (LMWP) for renal drug targeting (1990) (0)
- Kinetically stable alkali cation complexes of calixspherands (1992) (0)
- ERYTHROCYTE NA+/LI+ COUNTERTRANSPORT AND NA+/K+-2CL- CO-TRANSPORT IN ESSENTIAL HYPERTENSION: AUTHORS' REPLY (1999) (0)
- Irbestartan is projected to be cost and life saving in the USA for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria (2003) (0)
- 25 – Pathogenesis, Pathophysiology, and Treatment of Diabetic Nephropathy (2014) (0)
- Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. (2022) (0)
- Increased Levels of Urinary Albumin: A Cardiovascular Risk Factor and a Target for Treatment (2010) (0)
- European clinical coordination Center for the Sulodexide Trial (2005) (0)
- 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial (2021) (0)
- Calixspherands for the use in medicine (1991) (0)
- P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM (2020) (0)
- Altering the dosing time of trandolapril does not increase the antiproteinuric effect of ACE inhibition in non-diabetic kidney disease (2008) (0)
- Original Contribution Evaluation of Measures of Urinary Albumin Excretion (2006) (0)
- Chapter 5 pREdIcTORS Of RENal fUNcTION dEclINE IN ThE GENERal pOpUlaTION dIffER by GENdER (2010) (0)
- optimising renoprotective therapy ? Between-patient differences in the renal response to renin-angiotensin system intervention : clue to (2002) (0)
- Improved Cardiovascular and Renal Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program Irrespective of Baseline (BL) Body Mass Index (BMI) (2018) (0)
- Renal Function and Cardiovascular Diseases (2010) (0)
- Abstracts of papers and posters Meeting on Pharmaceutical Sciences (1993) (0)
- Small artery tone under control of the endothelium (2017) (0)
- FP158EFFICACY OF THE ANGIOTENSIN RECEPTOR BLOCKER LOSARTAN DURING HIGH POTASSIUM INTAKE IN CKD PATIENTS (2019) (0)
- The authors reply. (2014) (0)
- University of Groningen A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 (2017) (0)
- Subject Index, Supple 1, Vol. 55, 1990 (1990) (0)
- S-09-1: HIGH BLOOD PRESSURE AND ALBUMINURIA, BOTH THERAPEUTIC TARGETS FOR CARDIOVASCULAR DISEASE PROTECTION? (2023) (0)
- Have rational therapeutic principles emerged in treating hypertension in chronic renal failure? (1993) (0)
- 26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE (2020) (0)
- [The floating kidney]. (1997) (0)
- Management of chronic renal failure. (1992) (0)
- Targeting proteinuria as a valid surrogate for individualized kidney protective therapy. (2008) (0)
- Predict Cardiovascular Outcomes in Patients with Diabetes ? (2013) (0)
- P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL (2020) (0)
- P295 drug targeting of ace-inhibitors to the kidney with low molecular weight proteins (1994) (0)
- FP360VITAMIN D STATUS, SODIUM INTAKE AND THE RISK OF DEVELOPING CHRONIC KIDNEY DISEASE (2015) (0)
- Angiotensin-II-receptor blockers and nephropathy in patients with type 2 diabetes (2001) (0)
- Blood Pressure Response to Atrial Natriuretic Peptide (ANP) in Essential Hypertension (EH): Increased Sensitivity After Sodium Depletion (1986) (0)
- University of Groningen Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight Koomen, (2018) (0)
- 1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) (2020) (0)
- FP484DIFFERENT eGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM (2019) (0)
- Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study (2022) (0)
- Can angiotensin II be used for renoprotection (2002) (0)
- Pharmocoeconomic aspects of losartan treatment to delay progression of renal disease inpatients with Type 2 diabetes (2003) (0)
- Renal delivery of the ace inhibitor captopril (1996) (0)
- PS12 - 60. Not all performance measures of diabetes management predict better glycemic control (2012) (0)
- Preorganized Macrocyclic Ligands: A Novel Approach to Functionalized Hemispherands via Aromatization. (1988) (0)
- 27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease (2020) (0)
- Issue Highlights. (2015) (0)
- EFFICACY OF THE ANGIOTENSIN RECEPTOR BLOCKER LOSARTAN DURING HIGH POTASSIUM INTAKE IN CKD PATIENTS (2019) (0)
- deserve a lifestyle change (2014) (0)
- University of Groningen High Protein Intake Associates with Cardiovascular Events but not with Loss of Renal Function Halbesma, (2009) (0)
- Improved cardiovascular and renal outcomes in the CANVAS Program irrespective of baseline body mass index (2018) (0)
- Longitudinal relationship between albuminuria in infancy and childhood. (2023) (0)
- Gansevoort et al. Respond to “Using Measures of Albumin Excretion” (2006) (0)
- Trends in percentages of patients with elevated blood pressure levels and subsequent treatment modif (2011) (0)
- Rebuttal: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial? (2010) (0)
- Degree of proteinuria and progression of glomerular filtration rate fall in nondiabetic renal disease (1992) (0)
- Abstract 18957: Rationale, Design, and Analysis of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R) - A Randomized, Placebo-Controlled Trial (2016) (0)
- European Perspectives in Cardiology European Perspectives in Cardiology (2011) (0)
- Contents, Vol. 12, 1992 (1992) (0)
- [Renal effects of angiotensin-converting enzyme inhibitors: from the feared side effect to the desired treatment goal]. (1991) (0)
- Calixspherand complexes with possible medical applications (1993) (0)
- P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL (2020) (0)
- The future of Diabetic Kidney Disease management: reducing the unmet need. (2020) (0)
- University of Groningen A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness Sidorenkov, (2011) (0)
- [PP.35.20]: THE OVERLOOKED EFFECTS OF SULODEXIDE ON BLOOD PRESSURE A SYSTEMATIC REVIEW AND META-ANALYSIS (2015) (0)
- Early renin-angiotensin-system intervention is more beneficial than late intervention in delaying end-stage renal disease in type 2 diabetes (2016) (0)
- Therapeutic perspectives in cardio-renal interaction (2004) (0)
- Do diabetic kidneys deserve a lifestyle change? (2014) (0)
- Reply (2020) (0)
- (Clinical) Trial and Error in Diabetic Nephropathy (2018) (0)
- CV4 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING IN THE FRENCH SETTING FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA (2003) (0)
- New renal guidelines; is more better? (2014) (0)
- Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD (2021) (0)
- C-reactiveis associated with renal function abnormalities in a non-diabetic (2003) (0)
- Subject Index Vol. 50, 1988 (1988) (0)
- Erythrocyte sodium-potassium co-transport in hypertension. (1983) (0)
- Author response for "The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial" (2021) (0)
- Change in urinary albumin excretion is predictive of cardiovascular outcome in normotensive patients with type 2 diabetes mellitus and microalbuminuria (2008) (0)
- Author response for "Renal hyperfiltration defined by high estimated glomerular filtration rate: a risk factor of cardiovascular disease and mortality" (2019) (0)
- Angiotensin Converting Enzyme Inhibitors and Progressive Renal Insufficiency (2020) (0)
- Screening for microalbuminuria. Authors' reply (2005) (0)
- Growth-Differentiation Factor 15 PredictsWorsening of Albuminuria in PatientsWith Type 2 Diabetes (2012) (0)
- [Effect of protein restriction on deterioration of kidney function]. (1997) (0)
- Renal function during antihypertensive treatment. (1995) (0)
- Abstract 14752: Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial (2019) (0)
- Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease (2022) (0)
- 2-OR: Impact of N Terminal Pro B-Type Natriuretic Peptide and High Sensitivity Cardiac Troponin on the Prediction of Death and Cardiovascular Events in High-Risk Patients with Type 2 Diabetes (2020) (0)
- 771 IMPORTANCE OF MONITORING ON-TARGET AND OFF-TARGET DRUG EFFECTS DURING RENAL/CV PROTECTION STRATEGIES (2012) (0)
- Influence of anaesthesia on renal hippurate handling during angiotensin-converting enzyme inhibition in unilateral renal artery stenosis. (1992) (0)
- DOES RENIN LOWER BLOOD-PRESSURE? (1978) (0)
- FP272A PANEL OF NOVEL BIOMARKERS REPRESENTING DIFFERENT DISEASE PATHWAYS IMPROVES PREDICTION OF RENAL FUNCTION DECLINE IN TYPE 2 DIABETES (2015) (0)
- Pre-renal success Reply (2012) (0)
- Best practice for hypertensive patients with kidney disease (2003) (0)
- Gene therapy in renal transplantation (2005) (0)
- 133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Dick de Zeeuw?
Dick de Zeeuw is affiliated with the following schools:
